Suppr超能文献

辅助化疗对肝内胆管癌患者的疗效:配对分析

The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis.

作者信息

Schweitzer Nora, Weber Tim, Kirstein Martha M, Fischer Mareike, Kratzel Anna-Maria, Reineke-Plaaß Tanja, Lehner Frank, Manns Michael P, Vogel Arndt

机构信息

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hanover, Germany.

Department of Cardiology, Angiology and Intensive Care, Klinikum Hildesheim, Senator-Braun-Allee 33, 31135, Hildesheim, Germany.

出版信息

J Cancer Res Clin Oncol. 2017 Jul;143(7):1347-1355. doi: 10.1007/s00432-017-2392-8. Epub 2017 Mar 17.

Abstract

PURPOSE

The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT).

METHODS

Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors.

RESULTS

Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients.

CONCLUSIONS

We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.

摘要

目的

本研究旨在确定接受手术切除的肝内胆管癌(ICC)患者的预后因素,并探讨辅助化疗(CT)的效果。

方法

纳入2000年至2015年间在汉诺威医学院接受治疗的ICC患者。对临床病理特征进行单因素和多因素分析。在配对生存分析中,根据这些预后因素对接受或未接受辅助CT的患者进行配对。

结果

共纳入210例患者。中位生存期为28.7个月,1年、3年和5年生存率分别为72.8%、29.6%和14.1%。多因素分析显示,淋巴结受累(p = 0.006,HR 1.84)、肿瘤较大(p = 0.013,HR 1.79)、血管侵犯(p = 0.038,HR 1.70)和凝血酶原时间延长(p < 0.001,HR 4.20)与生存率低显著相关。39例患者接受了辅助CT,其中60%有淋巴结受累。根据确定的预后因素,对25例接受和未接受辅助CT的患者进行配对。接受辅助CT的患者中位生存期为33.5个月,而对照组为18个月(p = 0.002)。1年、3年和5年生存率分别为96%、36%和12%,未接受治疗的患者分别为60%、4%和0%。

结论

我们确定了接受手术切除的ICC患者的几个预后因素。我们的数据支持对ICC患者使用辅助CT。前瞻性随机对照研究的结果将在未来阐明辅助CT的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验